Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERUCOV-VAC Phase 1 in healthy volunteers
NCT04691947Phase 1Completed
- Sponsor
- TÜSEB
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of turkovac in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by TÜSEB. Primary endpoint: Safety and tolerability of the COVID-19 vaccine at 43 days. Started Nov 2020; status: completed.
02
Drugs
turkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04691947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691947.